CSGALNACT1 — patent landscape

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
SCHEMBL2295087	1.00	20/20
SCHEMBL2295660	1.00	20/20
SCHEMBL2295988	1.00	20/20
SCHEMBL2296073	0.92	20/20
SCHEMBL2294815	0.86	20/20
SCHEMBL2295118	0.86	20/20
SCHEMBL2295121	0.86	20/20
SCHEMBL2294362	0.86	20/20
SCHEMBL2294376	0.86	20/20
SCHEMBL2295203	0.84	20/20
SCHEMBL2295208	0.84	20/20
SCHEMBL2293762	0.84	20/20
SCHEMBL2293666	0.84	20/20
SCHEMBL2293625	0.83	20/20
SCHEMBL2296241	0.83	20/20
SCHEMBL2294540	0.83	20/20
SCHEMBL2294543	0.83	20/20
SCHEMBL2294065	0.83	20/20
SCHEMBL2294481	0.83	20/20
SCHEMBL2294223	0.82	20/20

Clinical trials — most relevant to CSGALNACT1 by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
A Phase 1/2 Study of Intravenous Gene Transfer With an AAV9 Vector Expressing Human Beta-galactosidase in Type I and Type II GM1 Gangliosidosis	PHASE1/PHASE2	RECRUITING
Vaccine Treatment for Surgically Resected Pancreatic Cancer	PHASE1/PHASE2	COMPLETED
Study of Safety, Tolerability and Efficacy of PBGM01 in Pediatric Participants With GM1 Gangliosidosis	PHASE1/PHASE2	ACTIVE_NOT_RECRUITING
Diabetic Retinopathy Sulodexide Study	PHASE2	COMPLETED
CAR-T Cell Therapy Targeting GPC3 in Patients with Advanced GPC3-Positive Hepatocellular Carcinoma	PHASE1/PHASE2	NOT_YET_RECRUITING
Vaccine Treatment for Advanced Malignant Melanoma	PHASE1/PHASE2	COMPLETED
Phase I Clinical Study of Chondroitin Sulfate for Treatment of NEC	PHASE1	WITHDRAWN
A Phase 1 Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of ManNAc in Subjects With Primary Podocyte Diseases	PHASE1	COMPLETED
Glycosylation in Patients With Galactosaemia	nan	COMPLETED
Histoblood Group Antigens as a Risk Factor of Asthma	nan	COMPLETED
Biomarker for Mucolipidosis Disorder Type I, II, III, IV (BioML)	nan	WITHDRAWN
Genome Environment Microbiome and Metabolome in Autism Study	nan	COMPLETED
A Retrospective Study to Identify New Omics Biomarkers of Chronic/Persistent Low Back Pain	nan	COMPLETED
Chest Wall Deformities in Children - Epidemiological Data	nan	COMPLETED
Institution of an Italian Multicenter Database of Patients Affected by Diseases of Phosphate Metabolism	nan	NOT_YET_RECRUITING
Using D-Galactose as a Food Supplement in Congenital Disorders of Glycosylation	nan	COMPLETED
BMN 110 US Expanded Access Program	nan	APPROVED_FOR_MARKETING
Clinical Study Assessing the Effect of ZIVEREL® in Cancer Patients	nan	UNKNOWN
Evaluation of Blood Protein O-GlcNAcylation Levels in Children	nan	RECRUITING
Intra-articular Hyaluronic Acid Injection for Accelerating Functional Recovery After Knee Arthroscopy	nan	COMPLETED
Safety and Efficacy of Continued CS1 Treatment of Patients With Pulmonary Arterial Hypertension	nan	AVAILABLE
The Natural History of Sialidosis Type I	nan	RECRUITING
Evaluation of Blood and Cardiac Protein O-GlcNAcylation Levels in Cardiac Surgery in Children	nan	RECRUITING
Characterization of Proteoglycan Depletion in Femoroacetabular Impingement With T1ρ Magnetic Resonance Imaging (MRI)	nan	COMPLETED
Pharmacokinetics of Low Molecular Weight Heparin in Cancer Patients	nan	COMPLETED
A Natural History Study of Patients With GNE Myopathy and GNE-Related Diseases	nan	COMPLETED
Diagnostic Accuracy of Pleural Effusion Aspergillosis Biomarker Testing	nan	UNKNOWN
Respiratory Cathepsins, Proteases Inhibitors and Glycosaminoglycans (GAG) in Mucopolysaccharidosis	nan	COMPLETED
A Prospective Trial to Identify Biomarkers Involved in the Transition From Acute to Persistent Chronic Low Back Pain	nan	UNKNOWN
Natural History of Glycosphingolipid Storage Disorders and Glycoprotein Disorders	nan	RECRUITING

Related proteins — ESM-2 sequence neighbours (a CSGALNACT1 binder may also engage these)

Protein	Name	Similarity
Q8BJQ9	—	1.000	Q8BJQ9 →
Q8C1F4	—	1.000	Q8C1F4 →
Q8N6G5	—	1.000	Q8N6G5 →
Q5DTK1	—	0.983	Q5DTK1 →
Q66PG2	—	0.982	Q66PG2 →
O95461	—	0.980	O95461 →
Q66PG4	—	0.979	Q66PG4 →
Q66PG3	—	0.979	Q66PG3 →
Q9Z1M7	—	0.979	Q9Z1M7 →
Q70JA7	—	0.979	Q70JA7 →
Q66PG1	—	0.978	Q66PG1 →
Q811B1	—	0.977	Q811B1 →
Q6GMK0	—	0.976	Q6GMK0 →
Q812F8	—	0.975	Q812F8 →
Q5M854	—	0.975	Q5M854 →
Q5NDF2	—	0.975	Q5NDF2 →
Q9UQ53	—	0.974	Q9UQ53 →
Q812G0	—	0.974	Q812G0 →
A7E2Z9	—	0.974	A7E2Z9 →
Q6PA90	—	0.974	Q6PA90 →
Q8CHI9	—	0.974	Q8CHI9 →
P79282	—	0.974	P79282 →
P16975	—	0.973	P16975 →
Q6NRQ1	—	0.973	Q6NRQ1 →
Q8HYB2	—	0.973	Q8HYB2 →
Q4R854	—	0.972	Q4R854 →
Q5QQ56	—	0.972	Q5QQ56 →
O94985	—	0.972	O94985 →
Q5T7M9	—	0.972	Q5T7M9 →
Q5R634	—	0.972	Q5R634 →